Press release

CUTISS receives Swissmedic approval

CUTISS AG receives Swissmedic approval to commence Phase IIb denovoSkin™ Trials in burns in adults and children.

Zurich, November 02, 2017 – CUTISS AG today announced that it has received approval from
Swissmedic to commence two Phase IIb Trials using denovoSkin™ in the treatment of burns in adults
and children. In Switzerland, these Trials will be recruiting patients at two centers, the University
Children’s Hospital Zurich where Phase I was recently completed, and the University Hospital Zurich.
The Trials will expand to other two centers, The Dutch Burn Center in The Netherlands, and the
University Hospital in Birmingham in UK, subject to approval by the National Authorities. The Trials
are designed to treat up to 15 burn patients each.

“The aim of these Phase IIb Trials is to validate the efficacy of denovoSkin™ against standard of care in
burns” said Dr. Fabienne Hartmann, CTO at CUTISS AG. “We are also delighted to continue the Trials
where they originated, at University Children’s Hospital Zurich. We want to thank the patients and
their families who have taken part in the trials so far and those that will support our future efforts”,
said Dr. Daniela Marino, CEO at CUTISS AG.

About Burns

Every year in the world, more than 11 millions of people burn large areas of their bodies and need
surgical intervention to restore skin function. In many cases, standard of care leaves patients with
discomforting and debilitating scars. denovoSkin™ could significantly improve the life quality of
patients worldwide by reducing scarring after transplantation.

CUTISS AG is a Swiss biotech company, spin-off of the UZH, developing personalized skin graft
technologies for the treatment of a large spectrum of skin defects. Its first in line product denovoSkin™
has been tested in a Phase I Clinical Trial on pediatric patients at the University Children’s Hospital in
Zurich. EU Phase IIb Trials are funded by Wyss Zurich. denovoSkin™ has received Orphan Drug
Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™
promises to improve life quality of elective (reconstructive) patients, it is a scalable technology and it
can further be developed in terms of complexity by e.g. adding pigmentation.

CUTISS AG, Daniela Marino, +41 76 230 8046,,

CUTISS AG raises CHF 1 Mio. in seed financing

Funding brings resources to start scale-up production of denovoSkin™.

Zurich, Switzerland, September 1st 2017 – CUTISS AG, a biotech company spin-off of the University
of Zurich (UZH), focused on the development of personalized bioengineered skin graft products for the
treatment of skin defects, announces the closing of a seed financing round of CHF 1 million. CUTISS’
lead product denovoSkin™ has successfully completed Phase I in pediatric patients and will initiate Phase
II studies in Q3/2017. The funds raised with UZH Life Sciences Fund investor will be used to launch the
development of the automation of the production process for denovoSkin™.

“The timing of this financing is perfect and puts CUTISS in a competitive position to efficiently continue
development of its proprietary technologies and personalized medicine products.” said Dr. Daniela
Marino, CEO and co-founder of CUTISS. “Launching of the scale-up activities represents a major
milestone of our process development.” added Dr. Vincent Ronfard, CIO of CUTISS. “The automation
project will bring GMP manufacturing to another level.” said Dr. Fabienne Hartmann, CTO and cofounder
of CUTISS. “We believe in CUTISS’ innovative product denovoskin™ for treating patients
suffering from skin defects,”, stated Anja König from the Novartis Venture Fund.
CUTISS’ board of Directors is chaired by Prof. Dr. med. Martin Meuli, a Key Opinion Leader in surgery
and skin tissue engineering. In conjunction with the financing, Anja König is joining the board with its
other founding members Prof. Dr. Ernst Reichmann, who leads the Tissue Biology Research Unit at the
University Children’s Hospital in Zurich where denovoSkin™ was developed, and Dr. Daniela Marino.

Scroll to Top


Would you like to contact us as a journalist?


This website uses cookies to ensure you get the best experience on our website.